58. 肥大型心筋症 Hypertrophic cardiomyopathy Clinical trials / Disease details
臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05182658 (ClinicalTrials.gov) | June 1, 2022 | 21/12/2021 | Empagliflozin in Hypertrophic Cardiomyopathy | The Use of Empagliflozin in Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy;Heart Failure | Drug: Empagliflozin 10 MG;Drug: Placebo | Institute of Cardiology, Warsaw, Poland | Medical University of Bialystok;University of Eastern Finland;Amsterdam UMC, location VUmc | Not yet recruiting | 18 Years | 70 Years | All | 250 | Phase 3 | Poland |